Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer biomarkers

Harnessing immune checkpoint trial data in pediatric cancer

Nature Cancer volume 4, pages 444–446 (2023)Cite this article

Subjects

The response rates of pediatric cancers to immune checkpoint inhibitor therapies are disappointingly low, particularly when compared to the remarkable impact of these drugs in many adult cancers. A new study leverages clinical trial data to identify biomarkers that might improve patient selection in future clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: How the individual elements of the PedCAP score might be interacting in the tumor immune microenvironment.

References

  1. Geoerger, B. et al. Lancet Oncol. 21, 134–144 (2020).

    Article  CAS  PubMed  Google Scholar 

  2. Geoerger, B. et al. Lancet Oncol. 21, 121–133 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Davis, K. L. et al. Lancet Oncol. 21, 541–550 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Das, A. et al. Nat. Med. 28, 125–135 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nabbi, A. Nat. Cancer https://doi.org/10.1038/s43018-023-00534-x (2023).

    Article  PubMed  Google Scholar 

  6. Ayers, M. et al. J. Clin Invest. 127, 2930–2940 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cristescu, R. et al. Science 362, eaar3593 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ott, P. A. et al. J. Clin. Oncol. 37, 318–327 (2019).

    Article  PubMed  Google Scholar 

  9. Grobner, S. N. et al. Nature 555, 321–327 (2018).

    Article  PubMed  Google Scholar 

  10. Lin, A. & Yan, W. H. Front. Immunol. 10, 964 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kalaora, S. et al. Nat. Commun. 11, 896 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Binder, C. et al. Front. Immunol. 11, 1090 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Groom, J. R. & Luster, A. D. Exp. Cell Res. 317, 620–631 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ge, Y., Paisie, T. K., Chen, S. & Concannon, P. J. Immunol. 203, 2827–2836 (2019).

    Article  CAS  PubMed  Google Scholar 

  15. Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Front. Immunol. 12, 636568 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Paul J. Neeson; Paul G. Ekert.

Authors and Affiliations

  1. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Paul J. Neeson & Paul G. Ekert

  2. The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia

    Paul J. Neeson & Paul G. Ekert

  3. Murdoch Children’s Research Institute, Parkville, Victoria, Australia

    Paul G. Ekert

  4. Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia

    Paul G. Ekert

  5. School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia

    Paul G. Ekert

Authors
  1. Paul J. Neeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul G. Ekert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Paul J. Neeson or Paul G. Ekert.

Ethics declarations

Competing interests

The authors declare no competing interests

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neeson, P.J., Ekert, P.G. Harnessing immune checkpoint trial data in pediatric cancer. Nat Cancer 4, 444–446 (2023). https://doi.org/10.1038/s43018-023-00540-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00540-z

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer